Imperial College London
Alternate

Professor Toby Maher

Faculty of Medicine, National Heart & Lung Institute

Professor of Interstitial Lung Disease
 
 
 
//

Contact

 

+44 (0)20 7594 2151t.maher

 
 
//

Assistant

 

Ms Georgina Moss +44 (0)20 7594 2151

 
//

Location

 

364Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Kreuter:2021:10.1164/rccm.202003-0669oc,
author = {Kreuter, M and Lee, JS and Tzouvelekis, A and Oldham, JM and Molyneaux, PL and Weycker, D and Atwood, M and Kirchgaessler, K-U and Maher, TM},
doi = {10.1164/rccm.202003-0669oc},
journal = {American Journal of Respiratory and Critical Care Medicine},
pages = {74--81},
title = {Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis},
url = {http://dx.doi.org/10.1164/rccm.202003-0669oc},
volume = {204},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Rationale: There is an urgent need for simple, cost-effective prognostic biomarkers for idiopathic pulmonary fibrosis (IPF); biomarkers that show potential include monocyte count. Objectives: We used pooled data from pirfenidone and interferon gamma-1b trials to explore the association between monocyte count and prognosis in patients with IPF. Methods: This retrospective pooled analysis included patients (active and placebo arms) from four Phase III, randomized, placebo-controlled trials: ASCEND (NCT01366209), CAPACITY (NCT00287729 and NCT00287716), and INSPIRE (NCT00075998). Outcomes included IPF progression (≥10% absolute decline in percent predicted forced vital capacity, ≥50 m decline in 6-minute walk distance, or death), all-cause hospitalization, and all-cause mortality over 1 year. The relationship between monocyte count (defined as time-dependent) and outcomes was assessed using bivariate and multivariable models. Measurements and Main Results: This analysis included 2067 patients stratified by monocyte count (at baseline: <0.60 GI/L [n=1609], 0.60–<0.95 GI/L [n=408], and ≥0.95 GI/L [n=50]). In adjusted analyses, a higher proportion of patients with monocyte counts of 0.60–<0.95 GI/L or ≥0.95 GI/L versus <0.60 GI/L experienced IPF progression (p=0.016 and p=0.002, respectively), all-cause hospitalization (p=0.030 and p=0.003, respectively), and all cause mortality (p=0.005 and p<0.001, respectively) over 1 year. Change in monocyte count from baseline was not associated with any of the outcomes over 1 year and did not appear to be affected by study treatment. Conclusions: In patients with IPF, elevated monocyte count was associated with increased risks of IPF progression, hospitalization, and mortality. Monocyte count may provide a simple and inexpensive prognostic biomarker in IPF. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (h
AU  - Kreuter,M
AU  - Lee,JS
AU  - Tzouvelekis,A
AU  - Oldham,JM
AU  - Molyneaux,PL
AU  - Weycker,D
AU  - Atwood,M
AU  - Kirchgaessler,K-U
AU  - Maher,TM
DO  - 10.1164/rccm.202003-0669oc
EP  - 81
PY  - 2021///
SN  - 1073-449X
SP  - 74
TI  - Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis
T2  - American Journal of Respiratory and Critical Care Medicine
UR  - http://dx.doi.org/10.1164/rccm.202003-0669oc
UR  - https://www.atsjournals.org/doi/10.1164/rccm.202003-0669OC
UR  - http://hdl.handle.net/10044/1/86146
VL  - 204
ER  -
Download